As per MRFR analysis, the US Buerger's Disease Market Size was estimated at 130.2 (USD Million) in 2023. The US Buerger's Disease Market Industry is expected to grow from 138.6(USD Million) in 2024 to 319 (USD Million) by 2035. The US Buerger's Disease Market CAGR (growth rate) is expected to be around 7.873% during the forecast period (2025 - 2035).
Buerger's disease, a rare disease affecting the blood vessels, is gaining increased attention in the US due to the rising awareness of its connection to tobacco use and its implications for vascular health. Key market drivers include a growing population of smokers and the increasing prevalence of conditions such as peripheral artery disease, which often coexists with Buerger's disease. The US healthcare system is witnessing more healthcare practitioners focus on early diagnosis and treatment, spurred by initiatives aimed at reducing smoking rates and improving overall public health.
Opportunities in the US Buerger's disease market include innovations in treatment options, such as improved pharmacological therapies and advanced surgical interventions.Increased research funding from both governmental and private sectors is enabling investigations into the pathophysiology of the disease, which may unlock new avenues for treatment. Additionally, educational campaigns aimed at raising awareness about Buerger's disease can drive earlier diagnosis and intervention, capturing the interest of pharmaceutical companies looking to develop targeted therapies.
In recent times, clinical guidelines for managing Buerger's disease in the US have evolved, emphasizing the need for multidisciplinary care. This trend highlights the integration of vascular specialists, rehabilitation professionals, and smoking cessation programs to provide comprehensive management of the disease.Moreover, technological advancements such as telemedicine are offering patients better access to specialized care, especially in rural areas, making it easier to seek treatment for this debilitating condition. Overall, the US Buerger's disease market is shifting towards a more proactive and coordinated approach to patient care, reflecting broader trends in the country’s health landscape.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The prevalence of Buerger's Disease, which is also known as thromboangiitis obliterans, is notably increasing in the United States. According to the National Institutes of Health, Buerger's Disease primarily affects men aged 20 to 40, especially those who smoke or are exposed to tobacco. Approximately 15 percent of all vascular surgeons report treating Buerger's Disease patients each year, signifying a significant number within the 3 million vascular surgeries performed annually in the US.
This alarming prevalence is likely to fuel the US Buerger's Disease Market Industry as the demand for effective treatment options rises. Additionally, with the growing awareness among healthcare professionals and patients regarding vascular diseases, the recognition of symptoms associated with Buerger's Disease is increasing, leading to more diagnoses and consequently more treatment interventions. Moreover, initiatives by organizations such as the American Heart Association to educate on the risks of smoking and its direct link to this disease further highlight the oncoming growth in market demand.
Recent advancements in treatment methodologies for Buerger's Disease, including both pharmacological interventions and surgical options, are setting the stage for significant market growth in the US Buerger's Disease Market Industry. The US Food and Drug Administration has been reviewing and approving therapies aimed at improving blood circulation and reducing pain associated with Buerger's Disease. Moreover, patient management strategies are evolving with technologies that focus on personalized medicine, which could lead to effectiveness in treatment for patients based on their individual profiles.
The American College of Cardiology is advocating for ongoing Research and Development efforts in this field, noting that innovative interventions could potentially change the disease's natural course and improve patient quality of life significantly, thus driving the market positively.
Government initiatives in the United States aimed at promoting awareness of Buerger's Disease and its impact are increasing, directly influencing the US Buerger's Disease Market Industry. The Centers for Disease Control and Prevention have launched public health campaigns to inform the community about the dangers of tobacco use and its link to vascular diseases like Buerger's Disease. Furthermore, increased funding for vascular health research through government grants is encouraging innovation in diagnostics and treatment methods.
The National Institutes of Health reported that funding for research in vascular diseases has grown by 12 percent over the past two fiscal years, enabling further exploration into Buerger's Disease. With the continued support from government entities to combat tobacco-related diseases, which are responsible for numerous vascular conditions, the market is poised for sustained growth.
The Symptoms segment of the US Buerger's Disease Market plays a crucial role in understanding the implications and management of this debilitating condition. Buerger's Disease is characterized by a range of symptoms that significantly impact patients' quality of life, with Pain, Ulcers, Gangrene, and Cold Hands and Feet being predominant manifestations. Pain is often the first noticeable symptom, predominantly affecting the extremities, which can lead to persistent discomfort and even disability. The presence of Ulcers, a direct consequence of reduced blood flow, can serve as a significant marker of disease severity and can complicate treatment strategies due to the potential for infection.
Gangrene represents a severe complication where tissue death occurs, often necessitating surgical intervention or in extreme cases, amputation, thereby underscoring the dire need for effective management of symptoms. Cold Hands and Feet are also prevalent, stemming from the vascular issues inherent in Buerger's Disease, leading to significant discomfort and limitations in daily activities. The combination of these symptoms affects not only the physical well-being of patients but also their mental and emotional health, creating a compounding effect that challenges both patients and healthcare providers.
With growing awareness of Buerger's Disease and its symptoms, there are opportunities for the development of targeted therapies and improvement in patient management strategies. This segment is critical as it guides healthcare professionals in diagnosing and tailoring treatment plans, whilst also highlighting the significant burden of the disease. The emphasis on symptom management is vital for improving the overall quality of life for patients, making it a focus for innovation in the US Buerger's Disease Market.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Treatment Type segment of the US Buerger's Disease Market plays a crucial role in addressing the complexities of this vascular condition. Medication is essential in managing symptoms and slowing disease progression, focusing on anti-inflammatory drugs and vasodilators that enhance blood flow. Surgical Procedures, while less common, can be significant for advanced cases, offering interventions that aim to restore circulation and alleviate pain. Lifestyle Changes are also vital, as they empower patients to improve their health outcomes through cessation of smoking, dietary adjustments, and exercise.
This holistic approach ensures a comprehensive strategy, targeting both symptom management and lifestyle enhancement, fostering better patient adherence and engagement in their treatment plans. Such factors contribute to the broader US Buerger's Disease Market revenue by addressing varying patient needs through diverse treatment options while also influencing the market growth trajectory and showcasing a shift towards patient-centric care. The increasing prevalence of risk factors in the US population underscores the growing importance of these treatment avenues, steering towards a more integrated healthcare approach in the management of Buerger's Disease.
The Diagnosis Method segment of the US Buerger's Disease Market plays a crucial role in the identification and management of this vascular condition, which predominantly affects younger male smokers. Within this segment, various methodologies are employed, each serving its unique purpose in diagnosis. Physical Examination is often the first step, allowing healthcare professionals to assess symptoms and initial patient history, which is critical for timely diagnosis. Doppler Ultrasound provides non-invasive vascular imaging, enabling clinicians to evaluate blood flow and obstruction in the arteries, which is a significant factor in Buerger's Disease, as reduced circulation is a hallmark of the condition.
Angiography, on the other hand, acts as a definitive diagnostic tool, providing detailed visuals of the blood vessels, which aids in understanding the severity of the disease. The integration of these methods enhances the effectiveness of clinical assessments, shaping the treatment plans for patients. As the awareness around Buerger's Disease grows, the importance of advanced diagnostic methods in the US market continues to expand, further driving market growth and development in this specialized area of healthcare. Overall, these diagnostic methods contribute significantly to the US Buerger's Disease Market segmentation by improving early detection and personalized treatment approaches.
The Patient Demographics segment of the US Buerger's Disease Market provides critical insights into the distribution of patients affected by this condition, emphasizing the significance of age group, gender, and smoking status in understanding the disease's impact in the United States. Primarily, Buerger's Disease predominantly affects younger individuals, particularly those in their twenties to forties, underscoring the importance of awareness and early diagnosis in this age bracket. Gender differences are also notable, as the disease tends to have a higher prevalence among males, which may correlate with higher smoking rates historically observed in this demographic.
Smoking status plays a pivotal role, as it is a major risk factor for the disease; many patients are either current or former smokers, highlighting the need for targeted smoking cessation programs and education. This demographic information is vital for developing effective interventions, understanding the characteristics of affected individuals, and optimizing treatment strategies tailored to these specific population groups within the US Buerger's Disease Market. Overall, the dynamics of patient demographics reveal essential trends that guide healthcare responses and management approaches for Buerger's Disease in the country.
The US Buerger's Disease Market has garnered significant attention due to the growing prevalence of this rare vascular condition, which primarily affects the blood vessels in the limbs. The competitive landscape is characterized by a diverse array of pharmaceutical companies focusing on novel treatment modalities and the enhancement of existing therapies. Companies are leveraging advanced research and development initiatives to innovate and create new solutions for patients suffering from Buerger's Disease while also working on improving patient awareness and engagement. The market is shaped by various dynamic factors including regulatory frameworks, competitive strategies, and evolving treatment methodologies, making it a critical area for stakeholders looking to establish or enhance their presence in this niche domain of healthcare.
Bristol Myers Squibb has established itself as a formidable player within the US Buerger's Disease Market, showcasing its commitment to addressing the needs of patients affected by this condition. The company’s strong portfolio of innovative therapies highlights its emphasis on research and development, enabling it to provide effective treatment options tailored to the unique challenges posed by Buerger's Disease. Bristol Myers Squibb benefits from its solid reputation and trust built with healthcare professionals and advocacy groups, which aids in driving awareness and adoption of its therapeutic solutions. Moreover, the company leverages its extensive distribution network and partnerships to ensure access to its products while continually investing in clinical trials and studies that reinforce its position in treating vascular diseases.
AstraZeneca, while notable for its wider range of therapeutic areas, also participates actively in the US Buerger's Disease Market. The company provides targeted therapies designed to address the underlying mechanisms associated with this condition and focuses on maximizing patient access to novel treatments. AstraZeneca's strengths lie in its robust pipeline of products and its ability to integrate advancements in technology and data analytics to improve outcomes. The company's market presence is further enhanced by strategic mergers and acquisitions, allowing it to expand its capabilities and resources in pursuit of innovative therapies. AstraZeneca’s commitment to research and the development of new drugs targeted specifically toward vascular diseases reflects its long-term vision, making it a key competitor in the US Buerger's Disease Market landscape.
Recent developments in the US Buerger's Disease Market have seen significant interest, particularly in treatment options and market growth. Companies such as Bristol Myers Squibb, AstraZeneca, Novartis, and Merck are actively exploring innovative therapies to address this condition, which primarily affects young men and is associated with tobacco use. In August 2023, Eli Lilly announced progress in its clinical trials for a novel treatment aimed at reducing symptoms of Buerger's Disease. The market has experienced growth in valuation due to the increasing demand for specialized therapies, alongside a rise in awareness programs initiated by various health organizations advocating for better understanding of the disease.
Furthermore, in November 2022, Gilead Sciences completed its acquisition of a smaller biotech firm focused on vascular inflammatory diseases, bolstering its position in the market. Regulatory updates from the US Food and Drug Administration are also impacting the approval processes for advanced therapies, enhancing the competitive landscape among key players such as Regeneron Pharmaceuticals, Pfizer, and AbbVie, who are all eyeing strategic collaborations to drive innovation in treatment options.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 130.2(USD Million) |
| MARKET SIZE 2024 | 138.6(USD Million) |
| MARKET SIZE 2035 | 319.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.873% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Bristol Myers Squibb, AstraZeneca, Novartis, Merck, Eli Lilly, Celgene, Gilead Sciences, Regeneron Pharmaceuticals, Pfizer, Amgen, AbbVie, Roche, Sanofi, Johnson and Johnson, Teva Pharmaceuticals |
| SEGMENTS COVERED | Symptoms, Treatment Type, Diagnosis Method, Patient Demographics |
| KEY MARKET OPPORTUNITIES | Increasing awareness and diagnosis, Development of targeted therapies, Expansion of clinical trials, Growth in telehealth services, Collaboration with patient advocacy groups |
| KEY MARKET DYNAMICS | Increasing prevalence of disease, Growing awareness and diagnosis, Limited treatment options available, Rising research and development efforts, Demand for advanced therapies |
| COUNTRIES COVERED | US |
Frequently Asked Questions (FAQ) :
The US Buerger's Disease Market is expected to be valued at 138.6 million USD in 2024.
By 2035, the US Buerger's Disease Market is projected to reach 319.0 million USD.
The expected compound annual growth rate for the US Buerger's Disease Market from 2025 to 2035 is 7.873%.
Among the symptom segments, 'Gangrene' holds a significant market value of 40.2 million USD in 2024.
The 'Pain' segment is projected to reach a market value of 75.0 million USD by 2035.
Major players in the US Buerger's Disease Market include Bristol Myers Squibb, AstraZeneca, and Novartis among others.
The 'Ulcers' segment is anticipated to reach a market value of 70.0 million USD by 2035.
The 'Cold Hands and Feet' segment is valued at 34.0 million USD in 2024.
The 'Gangrene' segment is expected to grow significantly, with projections reaching 90.0 million USD by 2035.
Challenges in the US Buerger's Disease Market include patient awareness and the availability of effective treatments.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
